Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In reply to Rao et al

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):693-4. doi: 10.1016/j.ijrobp.2014.03.014.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / surgery*
  • Humans
  • Lung Neoplasms / surgery*
  • Radiosurgery / methods*